SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Barbara Jordan — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientBarbara Jordan
Date of birth1936-02-21
IdentifiersMRN HR-ML030-SYN-TD; SSN (made up) 000-30-6852
Document date1980-04-20
AuthorEvangeline Moss, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Five-week review: second vaccine doses, baclofen titration, physical therapy, and readiness for the first infusion. [S]

History of Present Illness

Ms. Jordan returns five weeks after the consultation. Baclofen 5 mg three times a day made her drowsy for the first week; this has passed, and her mornings are less stiff. Mirabegron has helped: she now gets up once most nights. She had a sore arm for a day after the vaccines and no other reaction. She has had no new symptoms and no infection. The physical therapy evaluation requested at intake has not happened: the clinic's therapist with experience in multiple sclerosis has a waiting list, and she has not yet been offered a date. Her employer has agreed to the accommodations she asked for. She would like the infusions on days without teaching. [S]

ElementDetail
BaclofenDrowsy the first week, now settled; stiffness better
BladderUp once most nights on mirabegron
Physical therapyNot yet seen; waiting list
WorkAccommodations agreed

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever or infection
GenitourinaryNegativeUrgency better; no burning
MusculoskeletalPositiveMild morning stiffness
NeurologicalNegativeNo new numbness, weakness or visual change

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Cholecalciferol (vitamin D3) 1954 units (50 mcg) oral capsule, one capsule dailyOne capsule dailyOral route1980-03-02activeS
Baclofen 5 mg oral tablet, one tablet three times a day, to be increased to 10 mg three times a day once toleratedOne tablet three times a dayOral route1980-03-16 to 1980-04-20completedS
Baclofen 10 mg oral tablet, one tablet three times a dayOne tablet three times a dayOral route1980-04-20activeS
Mirabegron 25 mg extended-release oral tablet, one tablet dailyOne tablet dailyOral route1980-03-16activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1980-04-20Body height173cmS
1980-04-20Body weight83.8kgS
1980-04-20Body mass index (BMI) [Ratio]28kg/m2S
1980-04-20Systolic blood pressure120mm[Hg]S
1980-04-20Diastolic blood pressure76mm[Hg]S
1980-04-20Heart rate72/minS
1980-04-20Respiratory rate16/minS
1980-04-20Body temperature36.6CelS
1980-04-20Oxygen saturation in Arterial blood by Pulse oximetry99%S

Physical Exam

Vital signs recorded on 1980-04-20; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 120/76, pulse 72; temperature 36.6 °C
NeurologicalGait unchanged with a cane; modified Ashworth 1+ in both legs; hip flexor strength 4 out of 5, unchanged with baclofen
SkinNo rash; vaccine sites healed

Problems

ProblemClinical statusVerificationCodeProvenance
Multiple sclerosis diagnosed elsewhere, by her account, with records of the original evaluation not available: slowly worsening walking over the past few years, leg stiffness, fatigue, urinary urgency and heat sensitivity; uses a cane; course to be classified after MRI of the brain and spineresolvedconfirmed G35.DS — Synthetic presenting picture at intake, superseded by the classified diagnosis at the consultation; the cane and a diagnosis around the time she left Congress are from public accounts.
Active primary progressive multiple sclerosis: gradual worsening of walking over more than a year without relapses, with brain lesions in periventricular, juxtacortical and infratentorial regions, three spinal cord lesions, and one gadolinium-enhancing lesion; fulfils the 1971 McDonald criteria for primary progressive disease; EDSS 6.0; synthetic modern detail linked to her publicly reported multiple sclerosisactiveconfirmed G35.B1S — Synthetic course, MRI findings and disability score; the disease itself and her use of a cane are from public accounts.
Spastic gait from multiple sclerosis, walking with a cane, with two near-falls and no falls in the past year; at risk of fallsactiveconfirmed R26.89S — Synthetic modern coding anchored to her documented cane.
Neurogenic bladder from multiple sclerosis: urgency and getting up twice at night, with a low post-void residualactiveconfirmed N31.9S — Synthetic; common in multiple sclerosis. No public source describes her bladder.
Vitamin D deficiencyactiveconfirmed E55.9S — Synthetic laboratory finding at intake.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationNew or worsening symptoms (relapse, pseudo-relapse with heat or infection)Every visitCompleted todayNo new symptoms
ExaminationDisability: EDSS and timed 25-foot walkEvery visit, and at least every 6 monthsUp to dateEDSS 6.0 five weeks ago; gait unchanged today
ImagingBrain MRIAt diagnosis with gadolinium; re-baseline 3 to 6 months after starting therapy; then yearly without routine gadoliniumUp to dateDiagnostic MRI five weeks ago; re-baseline due three to six months after the first dose
Medication safetyVaccines before therapy (PCV20, recombinant zoster x2, Tdap, hepatitis B x2)Inactivated at least 2 weeks and live at least 4 weeks before the first doseCompleted todayZoster dose 2 and hepatitis B dose 2 today; series complete; first infusion two weeks from today
Medication safetyInfusion reactions and infectionsEach infusion, and every visitCompleted todayNo infection today; premedication and observation planned
ExaminationSpasticity (modified Ashworth) and baclofen toleranceEvery visitCompleted todayModified Ashworth 1+; baclofen increased to 10 mg three times a day
ExaminationBladder: urgency, nocturia, urinary infection, and blood pressure on mirabegronEvery visitCompleted todayNocturia once; blood pressure 120/76 on mirabegron
ReferralFalls, walking aids and physical therapyEvery visitDeferredMissed: the physical therapy evaluation requested at intake has not happened because of a waiting list. No harm so far: no falls and her gait is unchanged. Corrective action: the clinic asked the service today for the first available date, with a second provider if none is offered within three weeks; daily stretching and home exercises meanwhile
Self-managementWorkplace accommodationAt intake and with any changeCompleted todayAccommodations agreed by her employer

Goal progress:

Immunizations given today: Hepatitis B vaccine (HepB-CpG), dose 2 of 2; Recombinant zoster vaccine, dose 2 of 2 [S]

Guideline basis: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis (Rae-Grant A, et al.; PMID 29686116) (2018); 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis (Wattjes MP, et al.; PMID 34139157) (2021); Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis (Farez MF, et al.; PMID 31462584) (2019); OCREVUS (ocrelizumab) injection, prescribing information (2026); Multiple sclerosis in adults: management (NG220) (2022); Accommodation and Compliance: Multiple Sclerosis (2026); Introduction to the Americans with Disabilities Act (2026); Adult Immunization Schedule by Age (2026); CMID: Clinical Monitoring Intelligence Database, osteoporosis and depression monographs (2026)

Follow-up: Ocrelizumab infusions in two and four weeks at the infusion center. Review six weeks after the second infusion with a blood count, CD19 count, vitamin D and the PHQ-9. Next scheduled visit 1980-06-29: four-month review, six weeks after the first ocrelizumab doses: infusion tolerance, infections, blood counts, vitamin D, heat and mood. [S]